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Introduction
Colorectal cancer (CRC) is one of the leading causes of malignan-
cy-related death worldwide, with an increasing incidence (1). The 
disease status of patients can be classified according to histologic 
tumor grade (differentiation) and anatomic extent of the disease (i.e., 
tumor/node/metastasis [TNM], stages 1–4), which describes tumor 
growth into the wall of the rectum or colon (stage 2), involvement of 
regional lymph nodes (stage 3), and metastatic spread to other organs 
(stage 4) (2). Once metastasis has developed, 5-year survival rates fol-
lowing surgery are below 10% (3). Also, adjuvant chemotherapy after 
surgical resection for stage 3 CRC and high-risk stage 2 tumors (i.e., 
tumors with poor differentiation, T4 classification, lymphovascular 
invasion, or perineural invasion) increased patients’ survival rates, 
but many will relapse or develop distant metastases (4, 5). Thus, there 
is an urgent need to better understand the molecular changes leading 
to the development of CRC to identify novel therapeutic strategies.
An important risk factor for CRC development is inflammation. 
Patients with early-onset chronic inflammatory bowel disease (IBD) 
and widespread manifestation (i.e., pancolitis) have a higher prob-
ability of developing CRC (6). Furthermore, inherited mutations 
have been identified for 5% of patients with CRC, with diseases 
traditionally divided into polyposis syndromes, such as the famil-
ial adenomatous polyposis (FAP) and nonpolyposis syndromes like 
Lynch syndrome, also known as hereditary nonpolyposis colorectal 
cancer (HNPCC) (7). Sporadic CRC is a molecularly highly hetero-
geneous disease. Research teams from different institutions recent-
ly performed a meta-analysis of the different reported subclassifi-
cations to define the existence of 4 distinct gene expression–based 
subtypes (consensus molecular subtypes [CMSs]), i.e., immune 
(CMS1), canonical (CMS2), metabolic (CMS3), and mesenchymal 
(CMS4) (8). Each CMS has a unique biology and gene expression 
pattern (8), thus providing a framework for designing subtype- 
specific and personalized treatments. Indeed, CMSs have different 
clinical features including prognosis and response to therapies, with 
CMS4 having the worst prognosis.
Cyclin A2 is an established regulator of cell proliferation and 
has been used for molecular diagnostics as a proliferation mark-
er (9). However, several studies suggest that cell-cycle regulators 
can exert additional functions, well beyond cell-cycle control 
(10–16). For example, the cyclin CDK inhibitors p21, p27, and 
p57, as well as cyclin D1, have been found to be involved in the 
control of apoptosis, transcription, cytoskeletal dynamics as well 
as cell migration (12–13, 16)
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component in EMT and metastasis of lung cancer cells by mod-
ulating the TGF-β signaling pathway (20).
Few studies have investigated the role of cyclin A2 in tumor 
development in vivo using genetically altered mice. One study 
described the generation of mutant mice with reduced cyclin A2 
expression. These mice displayed spontaneous tumor develop-
ment, in particular in the lung, and were also more susceptible to 
We previously described a role for cyclin A2 in the regula-
tion of cell migration and invasion (17–19). More specifically, 
we found that deletion of cyclin A2 in a murine mammary gland 
epithelial cell line (NMuMG) induces epithelial-mesenchymal 
transition (EMT) and increases invasiveness in vitro as well as 
in vivo in an avian embryo model (18, 19). This concurs with 
a recent report that identified cyclin A2 as a key regulatory 
Figure 1. Cyclin A2 deletion leads to epithelial changes in the colon mucosa and inflammation. (A–C) Immunostaining for cyclin A2 (A), F4/80 (B), and 
IL-6 (C) of the indicated parts of colons from control (Ccna2fl/fl) and constitutive (VilCre Ccna2fl/fl) cyclin A2–deficient mice. Scale bars: 100 μm. Original 
magnification, ×2 (enlarged insets).
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Taken together, cyclin A2 deficiency in colonic epithelial cells (CECs) 
induces epithelial and architectural alterations of colonic crypts as 
well as different signs of inflammation.
RNA-Seq analysis reveals a prominent altered expression of genes 
involved in the cell cycle, the mitotic process, chromosome segregation, 
and DNA double-stranded break repair. To gain insights into the 
molecular traits of Ccna2-mutant mice, we performed RNA-Seq 
using CECs isolated from the proximal colon of Ccna2fl/fl mice (n = 
4) and VilCre Ccna2fl/fl mice (n = 4) at 4 weeks of age. At this age, 
VilCre Ccna2fl/fl mice already displayed visible distortion of the crypt 
architecture that was validated by immunohistochemical analysis 
of the distal region of the colons used in this experiment.
Notably, the RNA-Seq experiment validated the deletion of 
exons 2 to 7 of the Ccna2 gene and thus the efficient inactivation 
of cyclin A2 in CECs of VilCre Ccna2fl/fl mice (Supplemental Figure 
2A). Supervised analysis of the RNA-Seq data identified 469 upreg-
ulated and 640 downregulated genes in VilCre Ccna2fl/fl mouse 
samples versus Ccna2fl/fl mouse samples (fold change >2, adjusted 
P value |FDR| > 0.05) (Supplemental Table 1). Pathway analyses of 
the most altered genes revealed that the most significant biological 
functions associated with the genes upregulated in VilCre Ccna2fl/fl 
mice were related to the cell cycle (nuclear division and mitosis, 
regulation of the mitotic cell cycle, P < 2.79 × 10–3 to 1.15 × 10–12), cel-
lular assembly and organization (chromosome segregation, chro-
matin segregation, P < 3.01 × 10–3 to 1.80 × 10–9), as well as DNA 
replication, recombination, and repair (double-stranded break 
repair [DSB] and homologous recombination, P < 3.01 × 10–3 to 1.80 
× 10–9) (Supplemental Tables 1 and 2 and Supplemental Figure 2B). 
In line with this, the analysis highlighted increased levels of Mki67 
(coding for Ki67), Brca1, Brca2, Rad18, Rad51, Blm, Exo1, or Rpa1 
(genes involved in the DSB repair mechanism) as well as Cdc45, 
Bub1, Mad2, and Rad21 (genes related to checkpoint controls of the 
cell cycle and to abnormal mitosis) (Supplemental Figure 2C).
Cyclin A2 loss in CECs leads to increased proliferation of CECs 
and onset of dysplasia. To validate the RNA-Seq results described 
above at the functional level, we first tested the proliferation sta-
tus of cyclin A2–deficient CECs by measuring BrdU uptake. For 
this, mice received an intraperitoneal injection of the nucleoside 
analog BrdU and were sacrificed 2 hours later to isolate colons. We 
performed subsequent immunohistochemical analysis by dissect-
ing the different regions of the colon as described above (Supple-
mental Figure 1A) and by separating the bottom, middle, and top 
parts of the crypts. As shown in Figure 2A, BrdU+ cells were mainly 
located in the bottom of the crypts in control mice. In contrast, 
BrdU incorporation was most prominent in the middle part of the 
cyclin A2–deficient crypts, with an average of more than 4 cells per 
crypt (n = 60, P < 0.0001). Moreover, we detected BrdU+ cells in 
the upper crypts of VilCre Ccna2fl/fl mice but not in those of con-
trol mice. These specific profiles of BrdU incorporation of cyclin 
A2–deficient CECs were observed equally in the distal, transverse, 
and proximal regions. To confirm the increased proliferation rate 
of cyclin A2–deficient CECs, we analyzed Ki67, which is expressed 
during all active phases of the cell cycle (i.e., G1, S, G2, and M) but 
is absent in resting cells (29). We detected Ki67 expression in the 
distal region of colons at the bottom of the crypts in colons of con-
trol mice, but its expression was localized to the middle and upper 
parts of the colonic crypts of Ccna2-KO animals. We observed a 
chemically induced skin cancer (21). On the other hand, tissue-spe-
cific cyclin A2 inactivation in the liver was shown to impair hepa-
tocellular carcinoma development and recapitulated the phenotype 
observed in absence of cyclin-dependent kinase 2 (CDK2) (22). 
These observations point to a tissue-specific role of cyclin A2.
We previously reported lower cyclin A2 expression in hepat-
ic metastases compared with primary tumors derived from the 
same CRC patients (17). This prompted us to investigate the role 
of cyclin A2 in colon homeostasis and carcinogenesis using cell 
type–specific KO mice.
Results
Cyclin A2 depletion in the colon induces epithelial changes in the muco-
sa and inflammation. We established 2 mouse models to study the 
function of cyclin A2 in colon homeostasis and CRC development 
by using the previously established conditional cyclin A2 (Ccna2fl/fl) 
strain that is based on the Cre/LoxP system (23). Constitutive 
deletion of cyclin A2 in the intestinal epithelium was achieved by 
crossing cyclin A2 conditional–KO mice with the villin-Cre mouse 
strain (VilCre). Expression of Cre under the villin promoter was 
shown to be active in intestinal epithelial cells (24). In addition, 
we crossed Ccna2fl/fl mice with the inducible Cre mouse strain vil-
lin-CreERT2 (VilCreERT2), in which Ccna2 is excised upon intra-
peritoneal injection of tamoxifen (24).
We validated cyclin A2 loss in colonic crypts of VilCre Ccna2fl/fl 
mice by immunohistochemical analysis (Figure 1A). For this, we 
analyzed the distal region, close to the anus, as well as the proximal 
region, close to the cecum (Supplemental Figure 1A; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI131517DS1), since biological and clinical differences for both 
segments are well established (25). In both regions, we detected 
cyclin A2 expression in epithelial cells of the lower part of the crypts 
in control mice, whereas cyclin A2 expression was undetectable in 
colonic crypts of cyclin A2–KO mice (Figure 1A).
During the immunohistochemical analysis of cyclin A2 expres-
sion, we noted epithelial changes in the colonic crypts as well as 
architectural alterations in the mucosa of cyclin A2–deficient mice 
(Figure 1A and Supplemental Figure 1B). We also detected immune 
cell infiltration in cyclin A2–deficient colons. The immune cell 
infiltrates had morphological characteristics of macrophages and 
were immunostained using the macrophage marker F4/80. This 
revealed an increased number of F4/80+ cells, approximately 
2-fold in constitutive (Figure 1B and Supplemental Figure 1C, left 
panel) and 1.5-fold in induced (Supplemental Figure 1C, right pan-
el) cyclin A2–deficient colons versus normal ones. Macrophages 
can be important producers of the proinflammatory cytokine 
IL-6 (26), and, in fact, IL-6 was detectable in the stroma of cyclin 
A2–deficient colons but not in those of control mice (Figure 1C). 
Taking this one step further, we tested whether the infiltrating 
macrophages can be assigned to the M1 or M2 subtype, which have 
been attributed anti- and protumoral functions, respectively (27). 
Immunostainings for the M2 markers YM1 and TGF-β showed that 
colonic stroma of cyclin A2–deficient mice harbored predominant-
ly M2-polarized macrophages (Supplemental Figure 1D).
Moreover, approximately 15% of male and 10% of female VilCre 
Ccna2fl/fl mice developed rectal prolapses within the first 3 months 
of age, which can be considered an indicator of inflammation (28). 
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cyclin A2–deficient colons concur with the upregulation of Mki67 
transcripts detected in the RNA-Seq analysis.
We next tested whether expansion of the proliferative com-
partment in the middle part of cyclin A2–deficient crypts is asso-
ciated with reprograming toward a stem cell–like phenotype. For 
similar pattern in the proximal region of colons (Figure 2B and 
Supplemental Figure 3, A and B) from constitutive as well as 
induced KO mice (Supplemental Figure 3C), therefore confirming 
the observation made in the BrdU-uptake experiment. Thus, the 
elevated expression levels of Ki67 observed by immunostaining in 
Figure 2. Cyclin A2 depletion in CECs promotes cell proliferation. (A) Analysis of cell proliferation in colonic crypts of control (Ccna2fl/fl) and cyclin A2–
deficient (VilCre Ccna2fl/fl) mice by BrdU incorporation. Shown are representative images of immunostainings for BrdU of the distal and proximal parts of 
colons taken from Ccna2fl/fl and VilCre Ccna2fl/fl mice 2 hours after intraperitoneal injection of the nucleoside analog. Plots show quantification of the num-
ber of BrdU+ cells per crypt segment. Crypts (outlined in red in the images) were subdivided into 3 parts (dotted lines) for the analysis (bottom, middle, and 
top: n = 120 crypts for the distal and n = 110 crypts for the proximal parts of colons from 3 different mice). Data represent the mean ± SEM. ****P < 0.0001, 
by unpaired, 2-tailed Student’s t test. (B) Representative images of Ki67 immunostaining in the proximal part of colons from control animals (Ccna2fl/fl), 
induced KO mice 8 days after tamoxifen treatment (VilCreERT2 Ccna2fl/fl), and constitutive KO mice (VilCre Ccna2fl/fl). Scale bars: 100 μm.
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In addition, Western blot analysis of nuclear extracts derived 
from the constitutive KO mice displayed elevated levels of both 
active β-catenin and the NF-κB p65 subunit (Figure 5B, left panel). 
We also detected TAZ expression in crypts as well as surrounding 
stroma in colons of VilCre Ccna2fl/fl mice (Figure 5D, right panel).
To investigate the activation sequence of the different pathways 
modulated in cyclin A2–deficient CECs at the protein level, we took 
advantage of the inducible Cre mouse model (VilCreERT2 Ccna2fl/fl 
mice). Two tamoxifen injections on days 0 and 2 were sufficient to 
abrogate cyclin A2 expression in VilCreERT2 Ccna2fl/fl mice (Figure 
5B, middle and right panels). We performed Western blot analysis 
on days 2 and 4 upon Ccna2 depletion when the colons still showed 
no alterations such as changes in crypt architecture or immune cell 
infiltration (Supplemental Figure 7, A and B). We measured the 
expression levels of active β-catenin and NF-κB by Western blot-
ting (Figure 5B), as well as expression of γH2AX and TAZ by IHC 
(Figure 5, C and D, and Supplemental Figure 7A). In addition, we 
performed quantification of mitoses on H&E-stained colons from 
induced KO mice, also on days 2 and 4 (Supplemental Figure 7B, 
right panel). An increase in mitoses as well as DNA damage, mon-
itored by γH2AX staining, were already detectable on day 2 and 
were further increased on day 4 in cyclin A2–deficient CECs (Fig-
ure 5C, and Supplemental Figure 7, A and B). This concurs with the 
elevated number of Mre11 foci, which were detectable by day 2 on 
and progressed with time after cyclin A2 inactivation (Supplemental 
Figure 7C). In contrast, activation of β-catenin was only detectable 
on day 4, thus after the induction of DNA damage on day 2, whereas 
NF-κB and TAZ levels were unaltered at those time points (Figure 
5B, middle and right panels, and Figure 5D). To test whether elevat-
ed β-catenin activation (nuclear staining) and/or DNA damage are 
associated with the abnormal Ki67+ compartment in cyclin A2–defi-
cient colons, we performed costainings, which revealed that nuclear 
active β-catenin and γH2AX were predominantly present in the low-
er and upper parts of the crypts, respectively, and that these parts 
were devoid of Ki67 (Supplemental Figures 8 and 9).
To further explore the alterations in cyclin A2–deficient 
colonic epithelium, we generated organoids. During the process 
of extraction from colon, we noticed an increased fragility of the 
cyclin A2–deficient crypts, yielding a reduced number of crypts 
when compared with controls, with a mean of 2300 and 9500 
crypts per colon, respectively (n = 7, P < 0.001; Figure 6A). More 
important, while colon organoids derived from Ccna2fl/fl mice were 
budding on day 4 of culturing, the organoids derived from VilCre 
Ccna2fl/fl mice were mainly forming cysts in the presence of normal 
organoid media containing WNT3a (i.e., WENR media containing 
WNT3a, EGF, noggin, R-spondin) (Figure 6B). Cyst formation has 
been observed on intestinal organoids from APC-mutant mice (37). 
We therefore cultivated cyclin A2–deficient crypts in the absence of 
WNT3a (ENR media) and found them to be able to bud under this 
condition (Figure 6C). The formation of cysts in cyclin A2–deficient 
organoids appeared therefore be related to an increased activation 
of β-catenin signaling, thus concurring with the results obtained by 
Western blotting and immunohistological analysis of colons.
Cyclin A2 deficiency in CECs promotes colon carcinogenesis in 
mice. To test whether cyclin A2 deficiency modulates colon car-
cinogenesis, we subjected VilCre Ccna2fl/fl and Ccna2fl/fl mice to 
chemically induced colon carcinogenesis, an established mouse 
this, we used CD44v6, which was originally described as a mark-
er for constitutive and reprogrammed cancer stem cells (30) but 
was later found to also be expressed by cells at the bottom of nor-
mal colonic crypts, where colonic epithelial stem cells are local-
ized (31). Indeed, we detected distinct expression of CD44v6 by 
cells at the base of the normal crypts, but a strong upregulation of 
CD44v6 levels in the abnormal Ki67+ compartment of cyclin A2–
deficient crypts (Supplemental Figure 4).
Strikingly, in approximately 80% of the mice analyzed, colons 
deficient for cyclin A2, either constitutive or induced, revealed 
low- and high-grade dysplasia that was mostly found in the prox-
imal region (Figure 3, A and B). Constitutive KO mice showed 
an average occurrence of 4 low-grade dysplasias and nearly 2 
high-grade dysplasias per colon. Induced KO mice had a mean of 
approximately 3 low-grade and high-grade dysplasias per colon, 
whereas no dysplasia was detectable in the control mice (Figure 
3, C and D). Notably, dysplasia was already detectable 8 days after 
tamoxifen injection in VilCreERT2 Ccna2fl/fl mice.
Cyclin A2 depletion in CECs leads to abnormal mitoses and DNA 
damage. We further explored cell-cycle features and noticed an 
increased incidence of mitoses within the crypts when analyzing 
colons of constitutive and induced KO mice (on day 8). Colons 
with constitutive and induced Ccna2 deletion showed an average 
of 13 and 24 mitotic figures per mm2, respectively, whereas in con-
trol animals, we observed mitotic figures that were on average only 
2 per mm2 (n = 5, P < 0.01 for the constitutive as well as induced 
KO mouse strain) (Figure 4, A and B). In addition, CECs deficient 
for cyclin A2 harbored nuclear pleomorphisms characterized by 
increased nuclear size compared with controls (Figure 4A and 
Supplemental Figure 5). Finally, abnormal mitosis, detected by 
combined staining for α-tubulin to visualize mitotic spindles, γ-tu-
bulin to label centrosomes, and DAPI to identify chromosomes, 
was prominent in induced cyclin A2–deficient colons but not in 
control colons (Supplemental Figure 6, A and B).
Defective mitoses can lead to DNA damage (32), thus, we ana-
lyzed colons of tamoxifen-treated VilCreERT2 Ccna2fl/fl mice by 
IHC using a marker for DSBs, i.e., an anti-γH2Ax antibody, and 
found an average of more than 70 γH2AX+ cells/mm2 in cyclin A2–
deficient CECs compared with 40 in control CECs (Figure 4C; n = 
4, P < 0.05). Mre11 is part of the NMR complex involved in the res-
olution of dsDNA (33). We therefore analyzed Mre11 foci formation 
by confocal microscopy (34) and found that Mre11 foci formation 
was significantly increased in VilCre Ccna2fl/fl nuclei (Figure 4D).
Altogether, the alterations found at the protein level correlated 
with the RNA-Seq results, underpinning the presence of cell-cycle 
perturbations, increased DNA damage, and DNA DSB repair path-
way activation in cyclin A2–deficient CECs.
Activation of regenerative pathways in cyclin A2–deficient colons.  
Tissue injury induces inflammation and, in turn, a regenerative 
response (35). Several pathways have been described that can pro-
mote tissue repair in the intestine including YAP/TAZ, NF-κB, and 
WNT/β-catenin signaling (35, 36). We have previously shown that 
cyclin A2 inactivation in epithelial cells in vitro leads to increased 
β-catenin stability and activity (18, 19). For this reason, we first tested 
β-catenin expression in the colons of constitutive KO mice by immu-
nohistochemical analysis, which revealed increased nuclear localiza-
tion of β-catenin in CECs of cyclin A2–deficient colons (Figure 5A).
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model resembling the human pathology (38). This model depends 
on the intraperitoneal injection of the mutagen azoxymethane 
(AOM) and the subsequent induction of inflammation by adding 
dextran sodium sulfate (DSS) in the drinking water, and is there-
fore named colitis-associated carcinogenesis (CAC). DSS is toxic to 
mucosal epithelial cells, specifically in the colon, and the destruc-
tion of the mucosal barrier leads to chronic inflammation. In the 
classical protocol, mice receive 3 DSS treatments for 5 days within 
60 days, leading to tumor lesions in the distal region of the colon 
(38). VilCre Ccna2fl/fl mice displayed an approximately 2-fold great-
er weight loss on days 10 through 15 following the first DSS admin-
istration compared with control mice (Supplemental Figure 10). 
We therefore decided not to administer additional doses of DSS 
to the mice. Mice were sacrificed 60 days after the AOM injection, 
and colons isolated and embedded in paraffin. The grade of colitis 
was evaluated as described in Supplemental Table 3 (39) and was 
3-fold higher in cyclin A2–deficient mice (n = 6, P ≤ 0.05; Figure 
7A). Differences included submucosal alterations as well as trans-
mural disruption by immune cell infiltration, which was undetect-
able in control mice (Figure 7, A and B). The colon architecture was 
strongly affected in cyclin A2–deficient mice (Figure 7C), and  the 
incidence of low- and high-grade dysplasia was pronounced in the 
VilCre Ccna2fl/fl mice but was rather rare in the control animals (Fig-
ure 7D). Moreover, the surface area of both low- and high-grade 
dysplasias was significantly higher in the cyclin A2–deficient mice 
compared with the control animals (Figure 7E). In addition, ade-
nocarcinomas were only detectable in cyclin A2–deleted mice, but 
not in controls (Figure 7, D and E). Immunohistochemical analysis 
revealed increased expression levels of activated β-catenin, 
γH2AX, as well as IL-6 in cyclin A2–deficient colons compared with 
levels in the control animals (Figure 8).
We next evaluated the impact of cyclin A2 deletion on estab-
lished tumor lesions. For this, we exposed VilCreERT2 Ccna2fl/fl 
and Ccna2fl/fl mice to the classical AOM/DSS protocol described 
in Figure 9A and subsequently induced cyclin A2 deletion by 2 
consecutive tamoxifen injections. Approximately 40 days later, 
the mice were sacrificed for immunohistological analysis that 
revealed an increased number of adenocarcinomas in cyclin A2–
deficient colons (Figure 9B), which were characterized by elevated 
expression levels of the stemness marker CD44v6 (30) (Figure 9, 
C and D). Strikingly, invasive adenocarcinomas were detectable 
only in the proximal part of the colons of cyclin A2–deficient mice 
and absent in those of controls. Notably, the invasive adenocar-
cinoma displayed abundant CD44v6 expression, whereas the 
desmoplastic stroma of the invading tumors showed prominent 
TGF-β expression (Figure 9C).
Altogether, these observations show that cyclin A2 deficiency in 
CECs promoted chemically induced colon carcinogenesis in mice.
Cyclin A2 expression in patients with CRC has prognostic value. 
Our finding that cyclin A2 deficiency in mice promoted sponta-
neous development of dysplasia in the colon as well as induced colon 
carcinogenesis prompted us to perform a meta-analysis of CCNA2 
expression on available public data sets (Supplemental Table 4). The 
characteristics of the 2239 patients with CRC profiled are summa-
rized in Supplemental Table 5. Briefly, the median age of the patients 
was 68 years (range, 19–97 years), and the sex ratio was balanced, 
with 47% of female patients and 53% male patients. The most fre-
quent location was the right colon, followed by the left colon and 
sigmoid. The pathological stage included more stage 3–4 than stage 
1–2 cancers. The pathological grade was mostly 2, and the mismatch 
repair (MMR) status was microsatellite stable (MSS) in most cases. 
The CMS classification identified 20% of samples as CMS1 (micro-
satellite instability [MSI] immune), 32% as CMS2 (canonical), 17% 
as CMS3 (metabolic), and 31% as CMS4 (mesenchymal).
CCNA2 expression was heterogeneous across the 2239 primary 
CRC (pCRC) tumors analyzed (Figure 10A). Compared with nor-
mal colon (NC) tissues, CCNA2 transcript levels were upregulated 
in most of the primary tumors. In contrast, expression levels in CRC 
metastases (ANOVA, P = 4.16 × 10–54) were significantly lower com-
pared with levels in primary tumors (Figure 10A). In addition, we 
found that CCNA2 transcript levels were lower in the stages 3–4 ver-
sus stages 1–2 (Figure 10B). In parallel, we used 2 different cyclin A2 
antibodies to evaluate cyclin A2 protein expression by IHC on a tis-
sue microarray (TMA) of CRC biopsies taken from 65 patients from 
stage 1 to stage 4 (described in Supplemental Table 6) (Figure 10C, 
and Supplemental Figure 12A, and see Methods). We quantified 
cyclin A2 expression as the number of epithelium-positive cells per 
mm2 of tumor area. Immunohistochemical analysis confirmed the 
transcriptome data by revealing cyclin A2 protein levels to be lower 
in stages 3 and 4 than in early stages (Figure 10C, and Supplemental 
Figure 12A). In addition, we observed lower cyclin A2 levels in stage 2 
MSS compared with levels detected in MSI tumors (Figure 10C, and 
Supplemental Figure 12, A and B). We next evaluated CCNA2 levels 
according to the CMS classification (8) and observed that CCNA2 
expression was highest in the CMS1 class, lowest in the CMS4 class, 
and intermediate in the CMS2 and CMS3 classes (Figure 10E).
We next measured CCNA2 expression as a discrete value after 
comparison with the median expression of the 95 NC samples; 
upregulation, hereafter designated as CCNA2hi (n = 1139), was 
defined as a CRC/NC ratio of 2 or higher, and no upregulation, des-
ignated as CCNA2non-hi (n = 1100), was defined as a CRC/NC ratio 
of less than 2. We searched for correlations between the CCNA2hi or 
CCNA2non-hi classification and the clinicopathological and molecu-
lar variables of the 2239 pCRC samples (Supplemental Table 5) and 
found no correlation between CCNA2 mRNA levels and patients’ 
age or sex. By contrast, when compared with the CCNA2non-hi class, 
the CCNA2hi class was associated with more frequent right and left 
tumor locations (P = 2.04 × 10–2, Fisher’s exact test), pathological 
stages 1 and 2 (P = 3.19 × 10–8; Supplemental Table 5 and Figure 
10B), pathological grade 3 (P = 5.99 × 10–03), as well as MSI status (P 
= 1.48 × 10–5) and CMS1 molecular subtype (P = 1.00 × 10–6).
Relapse-free-survival (RFS) data were available for 1882 of 
2239 operated pCRC samples. The median follow-up was 42 
Figure 3. Dysplasia formation in cyclin A2–deficient mice. (A and B) Rep-
resentative images of H&E staining showing low-grade dysplasia (LGD) and 
high-grade dysplasia (HGD) in the colons of constitutive (VilCre Ccna2fl/fl) (A) 
and tamoxifen-induced (VilCreERT2 Ccna2fl/fl) KO (B) mice. Scale bars: 100 
μm. Original magnification, ×2 (enlarged insets). (C and D) Quantification of 
the number of low- and high-grade dysplasias and dysplasia areas (in mm2/
mm2 of colon) in constitutive VilCre Ccna2fl/fl (n = 7) mice and VilCreERT2 
Ccna2fl/fl induced KO mice 8 days after tamoxifen treatment (n = 8) versus 
control Ccna2fl/fl animals (n = 7). Data represent the mean ± SEM. Statistical 
analysis was performed using an unpaired, 2-tailed Student’s t test.
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underexpressed in the CCNA2hi class (Supplemental Figure 11C, 
and Supplemental Table 8). We used the gene expression signa-
ture (GES) of 92 genes based on the metagene analysis to classi-
fy samples. As expected, this GES allowed efficient classification 
of the 459 learning set samples (P = 1.08 × 10–52, Student’s t test). 
More important, we validated its robustness in a completely inde-
pendent validation set that included the 1780 remaining samples 
(P = 9.22 × 10–180, Student’s t test; Supplemental Figure 11B). A 
detailed analysis of the 92 genes revealed that the 20 most sig-
nificantly upregulated genes are involved in cell proliferation and 
DNA repair (mitotic cell-cycle regulation, genomic instability, and 
replicative immortality pathways) (Supplemental Table 8).
Discussion
Cyclins are well-established drivers of the cell cycle through 
activation of a specific family of kinases, the cyclin-dependent 
kinases (CDKs). Gene amplification as well as overexpression of 
cyclins have been frequently detected in cancer tissues, and cyc-
lins have been proposed as biomarkers or therapeutic targets (40). 
For example, inhibition of cyclin A2 complexes has been shown to 
impair the proliferation of some tumor cell lines (41).
Here, we report that cyclin A2 deficiency in CECs led to epithe-
lial changes in the mucosa, induced inflammation, and increased 
cell proliferation and dysplasia in the colon, rendering the mice 
more susceptible to chemically induced colon carcinogenesis. A 
higher incidence of mitoses as well as DNA DSBs were detectable 
as early as 2 days after cyclin A2 inactivation and appeared, there-
fore, to be the initial events, as elevated activation of β-catenin was 
only detectable on day 4, upon cyclin A2 deletion, followed later on 
by activation of NF-κB and TAZ. Therefore, cyclin A2 deficiency in 
CECs led to different molecular alterations, with DNA damage and 
abundant mitoses as the initiating events, followed by activation of 
β-catenin and the regenerative and inflammatory pathways involv-
ing TAZ and NF-κB. Our immunohistochemical analysis suggested 
a spatial separation of DNA damage and β-catenin activation in 
cyclin A2–deficient colons, with nuclear staining of active β-catenin 
being more frequent in the lower part of the colonic crypts, i.e., 
below the proliferative Ki67+ compartment, whereas γH2AX stain-
ing was localized in the upper crypt region (Supplemental Figures 
8 and 9). Furthermore, we found that the expanded proliferative 
Ki67+ compartment in cyclin A2–deficient colons gained a stem-like 
phenotype as revealed by immunostaining for CD44v6, an estab-
lished colon cancer stem cell marker and driver of metastasis (30).
It is well established that the WNT/β-catenin pathway triggers 
regeneration in certain tissues by controlling the stem cell com-
partment, and it has also been shown to cooperate with the YAP/
TAZ pathway during colonic tissue repair and regeneration (36, 
42). Furthermore, elevated NF-κB activation in combination with 
signals from the inflammatory microenvironment has been shown 
to increase WNT activation and lead to dedifferentiation of non-
stem cells in tumor-initiating and cancer stem cell entities (43–45). 
This could explain the acquisition of the CD44v6 stem-like pheno-
type of the proliferative cyclin A2–deficient cells localized in the 
middle parts of the crypts. On the other hand, 1 study showed that 
cyclin A2 is involved in stabilizing the axin/GSK3 destruction com-
plex, thereby promoting β-catenin degradation (46). This finding 
could explain the nuclear accumulation of β-catenin detected in 
months (range, 1–212); 496 patients (26%) had an event, and the 
5-year RFS was 70% (95% CI: 68–73; Supplemental Figure 11A). 
Interestingly, the clinical outcome was different between the two 
CCNA2-based classes, with 281 events (31%) in the CCNA2non-hi 
class (n = 894) versus 215 events (22%) in the CCNA2hi class (n = 
988; P = 2.32 × 106, Fisher’s exact test; Supplemental Table 5). 
The 5-year RFS was lower (65%) for CCNA2non-hi patients (95% 
CI: 61–69) versus 75% (95% CI: 72–79) for the CCNA2hi patients, 
respectively (P = 8.86 × 10–6; Figure 10D). In univariate analysis for 
RFS (Supplemental Table 7), the HR for the event was 0.67 (95% 
CI: 0.56–0.80) in the CCNA2hi class when compared with the HR 
for the CCNA2non-hi class (P = 1.01 × 10–5, Wald’s test). Other vari-
ables associated with RFS included the tumor location (P = 1.35 × 
10–6), the pathological stage (P = 2.78 × 10–15), and MMR status (P = 
2.97 × 10–4) (with the CCNA2non-hi class being predominantly asso-
ciated with MSS status, in agreement with the results obtained with 
the TMA), unlike patients’ age, sex, and pathological grade. In mul-
tivariate analysis (Supplemental Table 7), the CCNA2-based classi-
fication remained associated with RFS (P = 2.99 × 10–3, Wald’s test), 
as well as tumor location (right and sigmoid colon), pathological 
stage, and MMR status. Of note, this association remained signifi-
cant (P = 4.13 × 10–4) in multivariate analysis incorporating the CMS 
molecular classification (Supplemental Table 7). As shown in Figure 
10F, the RFS was affected for the 8 classes defined by both CCNA2 
expression levels and CMS (P = 1.82 × 10–6, log-rank test): CCNA2 
expression levels correlated with the clinical outcome for 3 CMSs, 
with a significantly reduced RFS for patients with CCNA2non-hi 
tumors compared with patients in the CCNA2hi class for CMS1 
(59% versus 73, P = 1.64 × 10–2), CMS3 (62% versus 79%, P = 0.05), 
and CMS4 subtypes (60% vs. 74%, P = 2.08 × 10–2) (Figure 10E).
To further explore the biological alterations associated with 
CCNA2 expression, we compared the whole-genome expression 
profiles of CCNA2non-hi (n = 222) and CCNA2hi (n = 237) The Can-
cer Genome Atlas (TCGA) samples (learning set) (Supplemental 
Figure 11,B and C). We identified 92 genes that were differen-
tially expressed, including 20 genes overexpressed and 72 genes 
Figure 4. Elevated mitoses and DNA damage following cyclin A2 deletion 
in the colonic epithelium. (A) Representative H&E staining showing an 
increased number of mitoses (red arrowheads) in the proximal region of 
colon from a cyclin A2–deficient mouse compared with colon from a control 
animal. Scale bar: 100 μm. Original magnification, ×2 (enlarged inset). (B) 
Quantification of mitotic events in constitutive mice (left: n = 5), induced 
KO mice 8 days after cyclin A2 inactivation (right: n = 5), and control animals 
(n = 5). Data represent the mean ± SEM. **P < 0.01, by unpaired, 2-tailed 
Student’s t test. (C) Immunohistochemical analysis of γH2AX expression in 
colon sections of control Ccna2fl/fl mice (n = 5) and VilCreERT2 Ccna2fl/fl   
tamoxifen–induced KO mice (n = 4) on day 8 following cyclin A2 inactiva-
tion. Representative γH2AX immunostaining images and quantification 
of the number of γH2AX+ cells per mm2 of epithelium from the proximal 
part of the colon are shown. Data represent the mean ± SEM. *P < 0.05, by 
unpaired, 2-tailed Student’s t test. Scale bar: 100 μm. Original magnification, 
×2 (enlarged inset). (D) Confocal analysis of nuclear foci formation of Mre11 
in crypts from the proximal part of colons from control Ccna2fl/fl and VilCre 
Ccna2fl/fl mice. Representative images are shown. Nuclei are stained with 
DAPI (blue) and Mre11 (red). Scale bar: 10 μm. Plot shows quantification of 
Mre11 fluorescence intensity per nuclear surface (n = 83 different nuclear 
areas for control mice and n = 65 for cyclin A2–deficient mice). Data repre-
sent the mean ± SEM. *P < 0.05, by unpaired, 2-tailed Student’s t test.
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DNA DSBs were shown to promote the production of IL-6 and the 
TGF-β family ligands (53, 54). Altogether, this suggests that the 
inflammatory response in cyclin A2–deficient mice is mounted as 
well in response to active genomic instability.
A large proportion of macrophages expressed YM1, indicating 
a predominant M2 polarization (Supplemental Figure 1C). Nota-
bly, M2-like macrophages have been described to promote tissue 
repair and remodeling and were attributed a protumoral role that 
could contribute to the phenotype of the cyclin A2–deficient mice 
(55). In addition, rectal prolapse was detectable in VilCre Ccna2fl/fl 
mice, a phenomenon that was previously described in a mouse 
model that develops colitis spontaneously (28). Increased expres-
sion and activation of NF-κB has been observed in IBD and in 
patients with CRC, especially in mucosal macrophages and epi-
thelial cells. This is accompanied by the production of cytokines 
including IL-6 and TGF-β, which have been proposed as thera-
peutic targets for the treatment of IBD (26, 56). Finally, YAP/TAZ 
overexpression has been shown to promote tumor formation (57) 
and to correlate with poor prognosis in CRC (58). We therefore 
conclude that DNA damage, combined with uncontrolled activa-
tion of several regenerative pathways, promotes the development 
of dysplasia in cyclin A2–deficient mice.
Most studies evaluating the prognostic value of cyclin A2 in 
CRC concluded that cyclin A2 overexpression is an indicator of poor 
prognosis (59–61), while 1 report described a higher survival rate for 
patients with tumors expressing high levels of cyclin A2 (62). To clar-
ify the prognostic value of cyclin A2 in CRC, we performed a meta- 
analysis of 11 publicly available transcriptome data sets comprising 
2239 primary tumor samples. This analysis revealed elevated CCNA2 
transcript levels in primary tumors compared with levels in normal 
tissues as well as metastases, concurring with our previous analysis 
of biopsies using immunohistochemical and Western blot analysis 
(17). CCNA2 transcript expression was higher in tumors of patients 
with stage 1 or 2 CRC compared with expression levels in patients 
with stage 3 or 4 disease. Importantly, this concurred with cyclin A2 
protein expression analysis by IHC on our TMA. Here, we show that 
CCNA2 expression differed among CMS subtypes, with the highest 
expression levels in the CMS1 subtype and the lowest in the CMS4 
subtype. We stratified the transcriptome samples from high and non-
high expressers by setting a cutoff of 2 or higher for the CCNA2 tran-
script expression ratio of CRC versus normal tissue and found higher 
RFS rates in the CCNA2hi class. Importantly, this favorable prognostic 
value of high CCNA2 expression persisted in multivariate analysis 
incorporating the classical prognostic factors or the CMS subtypes, 
suggesting an independent prognostic value. Whole-transcriptome 
supervised analysis of the two CCNA2 classes revealed that the 20 
most significant modulated genes upregulated in the CCNA2hi versus 
the CCNA2non-hi classes were all involved in cell proliferation and DNA 
repair. Although the expression data for multicellular tumor tissues 
cannot be directly correlated with the data obtained for cell type– 
specific KO mice, it is remarkable that CCNA2hi CRC tumors and 
cyclin A2 deficiency in murine CECs triggered similar mechanisms 
such as DNA damage. We also compared the GES of the RNA-Seq 
analysis from murine colons (Ccna2fl/fl versus VilCre Ccna2fl/fl mice) 
with the gene list used to establish the different CMS subtypes and 
found an overlap of 39 genes, among which 25 (>64%) belonged to 
the CMS4 subtype (Supplemental Figure 13). Most of these genes 
cyclin A2–deficient colons, as well. In line with this is our previous 
description that cyclin A2 depletion in murine mammary epitheli-
al cells promotes β-catenin activity (18, 19).
A previous study established a role of cyclin A2 in DNA DSB 
repair by generating mutant mice bearing cyclin A2–KO and hypo-
morphic alleles resulting in lower cyclin A2 expression (21). These 
mice fail to upregulate the meiotic recombination 11 (Mre11) nucle-
ase that causes impaired resolution of stalled replication forks, 
reduced repair of DNA DSBs, aberrant chromosome segregation, 
and increased spontaneous and chemically induced tumor devel-
opment (21). The same study reported that cyclin A2 binds to Mre11 
mRNA, thereby promoting its translation. We detected increased 
Mre11 foci formation in cyclin A2–deficient CECs, suggesting that 
the increased DNA damage detected in the colons of cyclin A2–defi-
cient mice resulted rather from a defective regulation of DNA repli-
cation and/or chromosome segregation. Indeed, phosphorylation of 
CDC6 by cyclin A/CDK2 has been shown to prevent re-replication 
during the S phase and G2 (47). Moreover, cyclin A2/CDK activity 
has been demonstrated to be essential for centrosome duplication 
and proper sister chromatid segregation (48). Of note, the mitoses 
detected in VilCre Ccna2fl/fl mice were mostly located in the middle 
part of the colonic crypts, whereas γH2AX+ cells were predominant-
ly identified in the upper part. This is in accordance with the fact 
that the generation of DSBs following abnormal mitosis takes place 
once a cell exits the mitotic process, entering the next cell cycle (49) 
thus during its migration toward the top part of the crypts. Nota-
bly, high expression levels of γH2AX have been shown to predict a 
poor prognosis for patients with CRC (50), and a more recent report 
described a role for cyclin A2 in preventing chromosomal defects 
(chromosomal instability [CIN]) in colon cancer cells (51).
It is well established that there is a crosstalk between DNA 
damage and inflammation and that either event can initiate the 
other one (52). Colons of cyclin A2–deficient mice displayed differ-
ent signs of inflammation with infiltration of macrophages as well 
as production of IL-6 and TGF-β, which correlated with increased 
activation of NF-κB in CECs. Recent findings suggest a direct rela-
tionship between chromosome mis-segregation, DNA damage, 
and the induction of a proinflammatory environment (52). In fact, 
Figure 5. Cyclin A2 deficiency triggers regenerative pathways. (A) Repre-
sentative immunostainings for active β-catenin in control (Ccna2fl/fl) and 
constitutive KO (VilCre Ccna2fl/fl) mice. Arrowheads indicate nuclear local-
ization of active β-catenin. Scale bar: 100 μm. Original magnification, ×2 
(enlarged insets). (B) Western blot analysis of active β-catenin and NF-κB 
in nuclear extracts of CECs derived from constitutive cyclin A2–deficient 
mice (n = 9), their littermate controls (left panel), and tamoxifen-induced 
KO mice (VilCreERT2 Ccna2fl/fl) following deletion of cyclin A2 on day 2 (n 
= 4, middle panel) and day 4 (n = 6 for β-catenin and n = 9 for NF-κB, right 
panel). Lower panels show quantification of active β-catenin and NF-κB 
after normalization with loading controls (TFIIB or histone H3). (C) Colons of 
cyclin A2–deficient mice displayed DNA damage. Plots show quantification 
of γH2AX staining in colons of control (n = 3) and VilCreERT2 Ccna2fl/fl (n = 4) 
mice on days 2 and 4 (n = 8) following tamoxifen-induced Ccna2 depletion. 
(D) Representative immunostainings of TAZ expression (indicated by 
arrowheads) in constitutive cyclin A2–deficient colons and induced KO mice 
on day 4 following Ccna2 deletion (left panel). Scale bar: 100 μm. Original 
magnification, ×2 (enlarged insets). Data represent the mean ± SEM. *P < 
0.05, **P < 0.01, and ***P < 0.001, by unpaired, 2-tailed Student’s t test.
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Figure 6. Cyclin A2–deficient organoids form cysts and only bud in the absence of WNT3a. (A) 
Number of Ccna2fl/fl and VilCre Ccna2fl/fl crypts extracted per colon. Data represent the mean ± SEM. 
**P < 0.01, by unpaired, 2-tailed Student’s t test. (B) Representative images of crypts extracted 
from colons of control (Ccna2fl/fl) and cyclin A2–deficient (VilCre Ccna2fl/fl) mice on days 0 and 4 of 
culturing in WNT3a-containing (WENR) media. Red circles indicate disrupted crypts. On day 4 of 
culturing, control organoids (left panel) were able to bud (indicated by red arrows), whereas cyclin 
A2–deficient organoids mainly formed cysts (right panel). Scale bars: 1 nm. (C) Representative 
images of VilCre Ccna2fl/fl organoids on day 6 of culturing in WENR media (cyst formation) or in the 
absence of WNT3a (ENR) media (budding, indicated by red arrows). Scale bars: 1 nm.
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For H&E staining, tissue slides were incubated in xylene (3 × 3 
min), 100% ethanol (3 × 3 min), 95% ethanol (3 min), and 80% eth-
anol (3 min) and then for 5 minutes in deionized water. Slides were 
then incubated in hematoxylin (Vector Labratories) for 3 minutes, 
extensively rinsed in tap water, and dipped in acid ethanol (0.03N HCl, 
70% ethanol). After rinsing in water, the slides were transferred into 
deionized water for 2 minutes and then stained in eosin for 30 seconds 
(Vector Laboratories), followed by 3 incubations of 5 minutes each in 
95% ethanol. After incubations in xylene, the coverslips were mount-
ed using Permount Mounting Medium (Thermo Fisher Scientific). For 
TMA analysis, the rabbit anti–cyclin A2 antibody (ab181591, Abcam), 
validated on Ccna2-deficient mouse tissues, as well as the rabbit anti–
cyclin A2 antibody (NCL-CYCLINA) were used (Supplemental Table 
10). Slides were scanned using the Nanozoomer scanner (Hamamatsu 
Photonics) and analyzed in NDP Viewer with gamma settings modified 
to accommodate for interslide variability of the HE staining.
For immunofluorescence analysis, the tissue slides were depar-
affinized and rehydrated as described above and incubated in 1 mM 
EDTA antigen retrieval buffer (pH 9.0) for α- and γ-tubulin, or in 10 mM 
citrate (pH 6) for anti-Mre11 staining. Blocking was performed for 30 
minutes in 2.5 % blocking serum, 5% BSA, and 5% nonfat milk at room 
temperature, and tissue slides were then incubated with primary anti-
bodies (see Supplemental Table 10) for 1 hour at 4°C. Depending on the 
primary antibodies, slides were incubated with goat anti-mouse, -rat, or 
-rabbit secondary antibodies conjugated to either Alexa Fluor 488 or 
Alexa Fluor 555 (Thermo Fisher Scientific) in addition to DAPI (0.1 
μg/mL) for 1 hour at room temperature. Mre11 staining images were 
acquired on the Leica Confocal SP5-SMD, and images were analyzed 
using Imaris software (Oxford Instruments). For costaining (i.e., α-/γ-tu-
bulin, Ki67/active β-catenin, Ki67/H2AX, and Ki67/CD44v6), image 
acquisition in the transverse and proximal colon was performed using 
Metamorph software (Molecular Devices) on the Upright Zeiss Axioim-
ager Z2 (Zeiss), and images were analyzed using ImageJ software.
BrdU incorporation assay. Mice were intraperitoneally injected with 
100 μg/g BrdU (B9285, MilliporeSigma) diluted in PBS. Colon speci-
mens were dissected 2 hours after injection, flushed with cold PBS, and 
embedded in paraffin after fixation in 10% formalin for 24 hours. Incor-
poration of BrdU was detected using an anti-BrdU antibody (Supplemen-
tal Table 10) after deparaffinization of the tissues, antigen retrieval in 
citrate buffer, and DNA denaturation using 2N HCl for 1 hour at 37°C fol-
lowed by an incubation in 0.1 M borax buffer, pH9. Revelation was per-
formed using the VECTASTAIN Avidin-Biotin Kit (Vector Laboratories).
Isolation of CECs. Colons were removed from mice, flushed with 
cold PBS, cut longitudinally, and treated with 10 mL CEC buffer (PBS, 
1% BSA, 1 mM EDTA, 1 mM DTT, 5.6 mM glucose) at 37°C for 45 
minutes under continuous shaking to release CECs. Cell purity was 
validated by FACS using the cell-surface markers EpCAM-APC and 
CD45-PE and CD90.2-FITC (see Supplemental Table 10) to identify 
epithelial and immune cells, respectively.
Isolation of CEC cytoplasmic and nuclear fractions. Cells were treat-
ed with ice-cold hypotonic buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 
0.1 mM EDTA, 0.1 mM EGTA, 0.5 mM PMSF, 1 mM DTT) and cOm-
plete Inhibitor Tabs (MilliporeSigma) for 15 minutes, and then treated 
with 10% NP40 and vortexed. The nuclei were pelleted by centrifuga-
tion (16.1 rcf, 15 s) while the supernatant was kept as the cytoplasmic 
fraction. Nuclei were lysed in 20 mM HEPES, pH 7.9, 0.4 mM NaCl, 
1 mM EDTA, 1 mM EGTA, 0.5 mM PMSF, 1 mM DTT, and cOmplete 
are known targets of TGF-β. This enrichment was significant (Fish-
er’s exact test, P = 5. 10–8). The CMS4 subtype, considered the “mes-
enchymal” class, is indeed defined by prominent TGF-β activation, 
stromal invasion, and angiogenesis and is characterized by a dismal 
survival outcome. Notably, the invasive adenocarcinoma we detect-
ed upon cyclin A2 deletion in the CAC-treated mice displayed CMS4 
features, such as stemness and TGF-β expression. We conclude that 
the expression pattern of cyclin A2 in CRC tissues mirrors distinct 
roles during colon carcinogenesis, such as driving cell proliferation in 
early stages, when highly expressed, but promoting aggressiveness in 
later stages, when expression levels are lower.
Taken together, our results establish that cyclin A2 deficiency in 
murine CECs induced DNA damage, inflammation, and activation 
of different regenerative pathways triggering dysplasia. This ren-
dered the mice more susceptible to chemically induced colon car-
cinogenesis by elevated tumor initiation as well as aggressiveness. 
Furthermore, cyclin A2 deletion in established tumors appeared to 
increase their aggressiveness. Our observations in mice were com-
plemented by a meta-analysis of 2239 pCRC tumors, which showed 
that high CCNA2 expression is associated with a better prognosis 
in patients with CRC. Moreover, we describe here for the first time 
to our knowledge that CCNA2 expression differs between CMS 
subtypes. Importantly, classification of the patient cohort into the 
different CMSs identified CCNA2non-hi expression as a poor prog-
nostic factor within CMS1, CMS3, and CMS4, but not CMS2. In 
conclusion, CCNA2 expression was strongly correlated with several 
clinicopathological factors of CRC and may represent a favorable 
prognostic marker in patients with CRC.
Methods
Generation of cyclin A2 conditional–KO mice in the intestinal epithelium. 
To generate cyclin A2 intestinal epithelium–specific KO mice, Ccna2 fl/fl 
mice, provided by P. Sicinski (Dana Farber Institute, Boston, Massachu-
setts, USA) (23), were crossed with transgenic mice carrying either a 
constitutively active Cre recombinase (vil-Cre) (provided by Sylvie Rob-
ine, Curie Institute, Paris, France) (24), expressed during embryonic 
development (day 9) throughout adulthood in intestinal epithelial cells, 
or a tamoxifen-inducible Cre under the same promoter (vil-Cre-ERT2) 
(provided by Robine, Curie Institute, Paris, France) (24), induced in 
adult mice by 2 intraperitoneal injections of tamoxifen (MilliporeSigma, 
150 mg/kg). Mice were maintained on a C57BL6 background. Geno-
typing was performed using the primers listed in Supplemental Table 9.
Immunohistochemical and immunofluorescence analyses of paraf-
fin-embedded tissue sections. Colons were rolled up lengthwise and 
embedded in paraffin after fixation in 10% formalin for 24 hours. Tis-
sue slides were deparaffinized and rehydrated in xylene (2 × 5 min), 
100 % ethanol (5 min), 96% ethanol (3 min), 70% ethanol (3 min), and 
dH2O (5 min). Tissue slides were incubated in 10 mM sodium citrate, 
pH6.0, for 20 minutes at 100°C or in 10 mM Tris, 1 mM EDTA, pH 9.0, 
for antigen retrieval, depending on the antibody. Following 2 washes 
in PBS–0.2% Tween 20, tissue slides were incubated in PBS with 3% 
hydrogen (H1009, MilliporeSigma) for 5 minutes at room temperature, 
blocked in 2.5 % blocking serum, 5% BSA, and 5% nonfat milk for 30 
minutes at room temperature, and then incubated with a primary anti-
body for 1 hour at 4°C. The corresponding secondary antibody reagents 
(ImmPRESS Kit, Vector Laboratories) were used for detection. The pri-
mary antibodies used are summarized in Supplemental Table 10.
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Figure 7. Cyclin A2–deficient mice are more susceptible to CAC. Ccna2fl/fl (n = 6) and VilCre Ccna2fl/fl (n = 7) mice were subjected to a modified AOM/DSS 
protocol including only 1 DSS treatment (Supplemental Figure 6A). (A and B). Quantification of the inflammatory scores for colons from control and VilCre 
Ccna2fl/fl mice (A) and representative H&E stainings showing transmural immune cell infiltration (indicated by the red oval) in KO mice (B) (the red arrows 
mark the muscularis mucosa). Scale bar: 100 μm. (C) Representative images of H&E-stained colons from control and cyclin A2–deficient mice subjected to 
the CAC protocol. Scale bars: 2 mm. (D and E) Number of dysplasia (LGD, HGD]) and adenocarcinoma (ADK) occurrences per mouse and dysplasia and adeno-
carcinoma area expressed in mm2/mm2 of colon in control and VilCre Ccna2fl/fl mice. Data represent the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, 
by unpaired, 2-tailed Student’s t test.
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values are expressed as the ratio of protein levels versus control with 
the TFIIB and histone H3 signal for the nucleoplasmic fraction. The 
complete unedited blots are shown in the supplemental material.
Colon organoids. Colons were washed extensively in cold PBS and 
penicillin-streptomycin and then cut into 0.5 cm pieces, which were 
placed into a 50 mL tube containing 10 mL cold PBS. The pieces were 
washed 5 to 10 times with cold PBS supplemented with antibiotics and 
then incubated in PBS and 25 mM EDTA on a roller for 30 minutes at 
4°C. After sedimentation, the pieces were successively washed 4 times 
Inhibitor Tabs (MilliporeSigma). The supernatant was collected as the 
nucleoplasmic fraction after centrifugation (16.1 rcf, 5 min).
Western blot analysis. Protein samples were prepared in 4× Laem-
mli buffer, separated in sodium dodecyl sulfate-polyacrylamide gels, 
and electro blotted onto nitrocellulose membranes (MilliporeSigma) 
using a wet/tank transfer system (Bio-Rad). The antibodies used for 
Western blotting in this study are listed in Supplemental Table 10. All 
the experiments were performed at least 3 times in triplicate. Quanti-
fication of immunoblots was carried out using ImageJ. Experimental 
Figure 8. Lesions in colons from cyclin A2–deficient mice exposed to CAC display elevated levels of active β-catenin, DNA damage, and IL-6 expression. 
Representative immunostainings for active β-catenin, γH2AX, and IL-6 in morphologically similar lesions in colons from control and cyclin A2–deficient 
mice at the end of the AOM/DSS protocol described in Supplemental Figure 10A. Scale bars: 100 μm. Original magnification, ×1.5 (enlarged insets).
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of 1.75% (w/v) DSS (TdB Consultancy AB) in the drinking water on day 5 
of the protocol. Mouse weights were checked every 2 days for 2 months, 
except for the week following the DSS treatment, when the weight was 
measured every day. Mice were then sacrificed and colons prepared 
for histological analysis after fixation in 10% formalin. Tissues were 
embedded in paraffin, and sections were stained with H&E or incu-
bated with primary antibodies (anti–active β-catenin, anti-γH2AX, and 
anti–IL-6), as reported above. Colitis was scored as outlined in Supple-
mental Table 3. For induction of CAC in the VilCreERT2 Ccna2fl/fl mice 
and their controls, mice were injected as described above with AOM 
but were treated 3 times with 1.75% DSS in the drinking water for 5 days 
on days 6, 30, and 50 of the protocol. Tamoxifen intraperitoneal injec-
tion was performed on days 63 and 65 to induce cyclin A2 inactivation, 
and mice were sacrificed on day 100 for analysis.
Patient samples. Details of the TMA generated at Centre de Res-
sources de l’Institut Régional du Cancer de Montpellier (CRB–ICM) 
(agreement number BB-033-00059) in Montpellier, France, are list-
ed in Supplemental Table 6. Some tissue samples were generated as 
duplicates from the same patients but were considered individual tem-
plates for the statistical analysis because of tumor heterogeneity.
For the transcriptome meta-analysis, we collected clinicopathologi-
cal and gene expression data on tissues from NC, pCRC, and metastatic 
CRC (mCRC) samples from 10 public data sets and 1 data set generated 
at the Institut Paoli Calmettes (Marseille, France) comprising at least 1 
probe set representing CCNA2. Sets and raw data were collected from 
the NCBI’s GenBank and GEO, ArrayExpress, and TCGA databases 
(Supplemental Table 4). Samples were profiled using whole-genome 
DNA microarrays (Affymetrix) or RNA-Seq (Illumina). The analyzed 
data set contained a total of 2401 samples, including 95 NC samples, 
2239 pCRC samples, and the 67 mCRC samples included in the present 
analysis, which were obtained from liver (n = 47) and lung (n = 20).
Gene expression data analysis. Data analysis required a step of 
preanalytic processing. We first normalized each data set separately 
using the robust multi-array average (RMA) (65) with the nonpara-
metric quantile algorithm for the raw Affymetrix data. Normalization 
was done in R using Bioconductor and associated packages. We then 
mapped hybridization probes across the different microarrays repre-
sented as previously reported (66). When multiple probes mapped to 
the same GeneID, the one with the highest variance in each data set 
was retained. The available TCGA RNA-Seq data that were already 
normalized were log2 transformed. Next, CCNA2 mRNA expression 
data were extracted and the batch effects corrected through the 11 
studies using z score normalization. Briefly, for each expression value 
in each separate study, CCNA2 values were transformed by subtract-
ing the mean of the gene in that data set divided by its SD, measuring 
the mean and SD of primary samples. CCNA2 expression was mea-
sured as a discrete value after comparison with median expression 
in the 95 NC samples; upregulation, thereafter designated CCNA2hi, 
was defined by a CRC/NC ratio of 2 or higher, and no upregulation 
(CCNA2non-hi) by a CRC/NC ratio below 2. The CMS classification (8) 
was based on the CMScaller tool made by Eide et al. (67). Finally, to 
explore the biological pathways associated with our CCNA2-based 
classification, a supervised analysis was applied using learning and 
validation sets. The learning set included the 459 samples of TCGA 
data set that included 222 CCNA2non-hi and 237 CCNA2hi samples. A 
moderated Student’s t test with empirical Bayes statistic included in 
the limma R packages was used. The FDR (68) was applied to correct 
in 10 mL cold PBS. The supernatant for each wash was strained in a 70 
μm mesh filter, and each fraction (F1-F4) was centrifuged at 600g for 
5 minutes and checked under the microscope for the presence of well-
formed crypts. In most cases, fractions 3 and 4 were used for the organ-
oid culture. A total of 200 crypts were resuspended in 50 μL Matrigel 
in either WENR media for the Ccna2fl/fl and VilCre Ccna2fl/fl crypts or 
ENR media for the VilCre Ccna2fl/fl crypts (Supplemental Table 11) and 
microscopically inspected once a day.
RNA-Seq sample preparation and bioinformatics analysis. CECs 
were isolated from the proximal colons of 4-week-old Ccna2fl/fl Vil-
Cre (KO) and Ccna2fl/fl (control) mice, as described above. RNA was 
extracted using the Roche High Pure RNA Isolation Kit (Roche Molec-
ular Systems), and purity as well as integrity were controlled using the 
Agilent RNA 6000 Nano Kit (Agilent Technologies). RNA-Seq was 
performed on an Illumina NextSeq 500 platform. Quantification of 
the gene transcripts was performed using the Kallisto program (63), 
which is based on the pseudoalignment principle, with default settings. 
GRCm38 RefSeq was used to annotate the transcripts. We used the 
STAR program (64) to align the reads on the Mus musculus reference 
genome (GRCm38/mm10). Raw data are available in the NCBI’s Gene 
Expression Omnibus (GEO) database (GEO GSE149716; https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE149716). For differen-
tial expression analysis (DEA), we first filtered the transcripts with 
too-low counts among the samples using the filterByExpr function of 
edgeR, with default settings. To perform the data normalization and 
DEA of Ccna2-deficient versus control samples, we ran standard steps 
of edgeR and DESeq2 in parallel on the filtered data. For both DEA 
methods, we applied a cutoff threshold of 0.05 to the adjusted P values 
and a cutoff threshold of 2 for the fold changes. The 2 resulting lists 
of significantly differentially expressed genes were intersected. We 
separated the upregulated and downregulated genes on this unique 
list. Finally, to perform functional enrichment analysis, these sublists 
were submitted to the dedicated function of the clusterProfiler pack-
age, available on Bioconductor (https://bioconductor.org/packages/
release/bioc/html/clusterProfiler.html). A Fisher’s exact or χ2 test was 
used when appropriate to analyze the enrichment of the CCNA2 signa-
ture with the published signatures of interest.
CAC. For induction of CAC in the VilCre Ccna2fl/fl mice and their 
corresponding controls, mice were intraperitoneally injected with 6.25 
mg/kg AOM (MilliporeSigma). Mice were treated with one 5-day cycle 
Figure 9. Inactivation of cyclin A2 on established tumor lesions leads to 
invasive adenocarcinomas. (A) Schematic representation of the AOM/
DSS protocol applied to VilCreERT2 Ccna2fl/fl (n = 8) and control (n = 8) mice. 
Note that cyclin A2 deletion was induced by tamoxifen injection after the 
last DSS treatment. (B) Quantification of the number of noninvasive versus 
invasive adenocarcinomas per mouse for control (Ccna2fl/fl) and cyclin A2–
deficient (VilCreERT2 Ccna2fl/fl) mice (n = 8 each). (C) Representative images 
of an invasive adenocarcinoma disrupting the muscularis mucosa and infil-
trating through the muscularis propria, as indicated by red lines. The panel 
on the left shows an immunostain for CD44v6 in tumor cells, and the panel 
on the right shows a focal immunostain for TGF-β in the desmoplastic 
stroma surrounding the tumor cells. Scale bars: 100 μm. Original magnifica-
tion, ×3 (enlarged insets). (D) Representative images of immunostains for 
CD44v6 on tumors of control and cyclin A2–deficient mice and correspond-
ing quantification of low and high CD44v6-expressing tumors. Tumors were 
classified as low expressers when less than 50% of the area had detectable 
CD44v6 expression. Scale bar: 100 μm. Data represent the mean ± SEM.
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Figure 10. High cyclin A2 expression correlates with a better prognosis in patients with 
CRC. (A) Box plots showing CCNA2 mRNA expression levels (log2 over NC) in pCRC (n = 
2239) and mCRC (n = 67) tumors. Expression was normalized to normal tissue samples. 
CCNA2hi levels were defined as expression above 1 (horizontal red line), and CCNA2non-hi 
levels were defined as expression below 1. For each box plot, the median and ranges 
are indicated. CCNA2 expression was compared between group using a multiple-com-
parison ANOVA. (B) CCNA2 mRNA expression levels in stage 1–2 (n = 834) and 3–4 (n = 
785) primary CRC tumors. Expression was normalized to normal tissue samples as in 
A. CCNA2 expression was compared between groups using a 2-tailed Student’s t test; 
data are expressed as the mean ± SD. (C) Cyclin A2 protein expression was determined 
by immunostaining using the anti–cyclinA2 antibody from Abcam validated on cyclin 
A2–deficient colon tissue and expressed as the number of positive cells per mm2 of 
tumor, analyzed from a TMA of CRC tumor samples derived from patients with stage 
1 (n = 23), stage 2 (n = 48, with 24 MSS tumors and 24 MSI tumors), stage 3 (n = 30), 
and stage 4 (n = 26) CRC. Data represent the mean ± SEM. *P < 0.05 and **P < 0.01, by 
unpaired, 2-tailed Student’s t test. (D) Kaplan-Meier RFS of patients defined as carriers 
of CCNA2hi (n = 988) or CCNA2non-hi (n = 894) tumors. Survival rates were calculated 
using the Kaplan-Meier method and compared with the log-rank test. (E) Analysis of 
CCNA2 mRNA levels in the different consensus CRC subtypes: CMS1 (n = 389), CMS2 (n 
= 640), CMS3 (n = 343), and CMS4 (n = 604) expressed as log2 over NC as described in A 
(multiple-comparison ANOVA). (F) Kaplan-Meier RFS curves for all patients with pCRC 
according to both the CCNA2-based classification (CCNA2hi and CCNA2non-hi classes with 
the solid curves and dashed curves, respectively) and CMS subtypes.
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the multiple testing hypothesis, and significant genes were defined 
by the following thresholds: a P value of less than 5%, a q value of 
less than 25%, and a fold change of greater than 2. The resulting GES 
was based on a metagene score defined as the difference between 
the mean expression of genes upregulated and the mean expression 
of genes downregulated in the CCNA2hi samples, using a cutoff of 0. 
This score was then applied to both learning and validation sets to 
test the robustness of the GES (Student’s t test). Gene ontology (GO) 
analysis of the gene list was based on GO biological processes of the 
Database for Annotation, Visualization, and Integrated Discovery 
(DAVID) (http://david.abcc.ncifcrf.gov/).
Statistics. Correlations between the CCNA2 expression–based 
classes (non-high versus high) and the clinicopathological factors 
were calculated using the Fisher’s exact test for binary variables and 
the Student’s t test for continuous variables. Our primary endpoint, 
RFS, was calculated from the date of diagnosis until the date of meta-
static relapse or death from CRC. The follow-up was measured from 
the date of diagnosis to the date of last news for event-free patients. 
Survival was calculated using the Kaplan-Meier method, and curves 
were compared with the log-rank test. Univariate and multivariate 
analyses were done using Cox regression analysis (Wald’s test). The 
variables tested in univariate analysis included the CCNA2-based 
classification (non-high versus high), patients’ age and sex, tumor 
location, pathological stage and grade, MMR status, and CMS classi-
fication. Multivariate analysis incorporated all variables with a P val-
ue below 5% in univariate analysis. All statistical tests were 2 sided at 
a 5% level of significance. Statistical analysis was done using the sur-
vival package (version 2.30) in R software (version 2.15.2). This arti-
cle was written in accordance with reporting recommendations for 
tumor marker prognostic studies criteria (REMARK) (69). Statistical 
analysis of quantifications in the mouse study was performed using 
GraphPad Prism (GraphPad Software). An unpaired, 2-tailed Stu-
dent’s t test was used, except for nuclear size distribution, for which 
the Kolmogorov-Smirnov test was performed using R software.
Study approval. Mouse experiments were performed in accor-
dance the European Community guidelines (86/609/EEC) and the 
French National Committee (87/848) for the care and use of labo-
ratory animals and were approved by the regional ethics committee 
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